

RECEIVED
CENTRAL FAX CENTER

SEP 23 2004

Please use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

Attorney Docket No.: 6150.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: 10/649,386

Group Art Unit: 1625

Filed: August 27, 2003

Examiner: Rita J. Desai

For: Use of Compounds for the Regulation of Food Intake

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed May 24, 2004, please amend the above-captioned application as follows:

Amendments to the Claims are reflected in the **Listing of Claims**, which begins on page 2 of this paper.

Remarks concerning the Office Action and the claim amendments begin on page 5 of this paper.

004 NVILLARI 00000006 141447 10649386

251 110.00 DA

Applicants enclose herewith the Sequence Listing for the above-captioned application. The computer-readable form in this application is identical with that filed in Application Serial No. 09/771,770 filed January 29, 2001. In accordance with 37 CFR 1.821(e), please use the last computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the attached paper entitled "SEQUENCE LISTING" and of the diskette filed in the parent application is the same. Furthermore, the information contained in the attached "SEQUENCE LISTING" and the ASCII-encoded file is identical to the information in the specification as originally filed. No new matter is added.

Address all future communications to Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ 08540.

Please charge the required fee, estimated to be \$1254, with this application and credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. Please charge any additional fees, should they be required, to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Date: August 26, 2003

23650

PATENT TRADEMARK OFFICE